KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Analyst Earnings Estimates
NASDAQ:KNSA - Nasdaq - GB00BRXB0C07 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 38.544M | 220.18M 471.24% | 270.259M 22.74% | 432.68M 60.10% | 580.73M 34.22% | 700.56M 20.63% | 816.64M 16.57% | 769.13M -5.82% | 1.005B 30.67% | 1.235B 22.89% | 1.417B 14.74% | 1.653B 16.65% | |
| EBITDA YoY % growth | -154.276M 0.44% | 12.173M 107.89% | -22.855M -287.75% | -33.51M -46.62% | 28.357M 184.62% | 57.289M 102.03% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -156.636M 0.46% | 9.773M 106.24% | -25.196M -357.81% | -27.795M -10.31% | 40.39M 245.32% | 47.862M 18.50% | 94.268M 96.96% | 114.24M 21.19% | 165.29M 44.69% | 350.98M 112.34% | 436.56M 24.38% | 567.12M 29.91% | |
| Operating Margin | -406.38% | 4.44% | -9.32% | -6.42% | 6.96% | 6.83% | 11.54% | 14.85% | 16.45% | 28.42% | 30.81% | 34.31% | |
| EPS YoY % growth | -2.30 10.85% | 2.59 212.61% | 0.18 -93.05% | -0.48 -366.33% | 0.43 190.21% | 0.84 93.40% | 1.50 79.27% | 0.79 -47.62% | 0.89 12.99% | N/A | N/A | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.00 -100.58% | 0.06 122.03% | 0.12 293.80% | 0.14 175.93% | 0.17 8,600.00% | 0.38 585.19% | 0.42 259.65% | 0.18 34.33% | 0.12 -29.41% |
| Revenue Q2Q % growth | 125.84M 50.90% | 130.61M 63.55% | 142.78M 38.10% | 153.75M 37.01% | 158.9M 26.27% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -12.24M -605.37% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -1.492M -1,942.04% | -929.557K 94.38% | 5.519M 4,817.09% | 8.741M 190.51% | 10.678M 815.66% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.18 10.00% | 0.03 | -0.21 | -651.47% |
| Q2 2024 Q2Q % growth | -0.06 -128.57% | -0.08 | 0.02 | 21.57% |
| Q1 2024 Q2Q % growth | -0.25 -38.89% | -0.17 | -0.08 | -50.06% |
| Q4 2023 Q2Q % growth | 0.35 483.33% | -0.14 | 0.49 | 345.10% |
| Q3 2023 Q2Q % growth | -0.20 -106.29% | -0.17 | -0.03 | -17.06% |
| Q2 2023 Q2Q % growth | 0.21 172.41% | -0.17 | 0.38 | 222.91% |
| Q1 2023 Q2Q % growth | -0.18 50.00% | -0.21 | 0.03 | 14.95% |
| Q4 2022 Q2Q % growth | 0.06 111.32% | -0.24 | 0.30 | 125.30% |
| Q3 2022 Q2Q % growth | 3.18 822.73% | 0.80 | 2.38 | 298.42% |
| Q2 2022 Q2Q % growth | -0.29 52.46% | -0.45 | 0.16 | 35.75% |
| Q1 2022 Q2Q % growth | -0.36 50.00% | -0.41 | 0.05 | 13.21% |
| Q4 2021 Q2Q % growth | -0.53 32.91% | -0.43 | -0.10 | -23.72% |
| Q3 2021 Q2Q % growth | -0.44 33.33% | -0.66 | 0.22 | 33.38% |
| Q2 2021 Q2Q % growth | -0.61 6.15% | -0.81 | 0.20 | 24.54% |
| Q1 2021 Q2Q % growth | -0.72 -50.00% | -0.74 | 0.02 | 2.64% |
| Q4 2020 Q2Q % growth | -0.79 -36.21% | -0.63 | -0.16 | -24.42% |
| Q3 2020 Q2Q % growth | -0.66 -34.69% | -0.62 | -0.04 | -6.95% |
| Q2 2020 Q2Q % growth | -0.65 4.41% | -0.64 | -0.01 | -1.80% |
| Q1 2020 Q2Q % growth | -0.48 62.20% | -0.65 | 0.17 | 25.77% |
| Q4 2019 Q2Q % growth | -0.58 | -0.63 | 0.05 | 8.29% |
| Q3 2019 Q2Q % growth | -0.49 | -0.73 | 0.24 | 33.05% |
| Q2 2019 Q2Q % growth | -0.68 | -0.73 | 0.05 | 7.08% |
| Q1 2019 Q2Q % growth | -1.27 | -0.82 | -0.45 | -55.64% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 112.214M 67.37% | 113.75M | -1.536M | -1.35% |
| Q2 2024 Q2Q % growth | 103.391M 44.66% | 94.159M | 9.232M | 9.80% |
| Q1 2024 Q2Q % growth | 79.858M 65.18% | 80.029M | -171K | -0.21% |
| Q4 2023 Q2Q % growth | 83.395M 34.76% | 73.459M | 9.936M | 13.53% |
| Q3 2023 Q2Q % growth | 67.046M -32.37% | 65.736M | 1.31M | 1.99% |
| Q2 2023 Q2Q % growth | 71.473M 164.99% | 53.24M | 18.233M | 34.25% |
| Q1 2023 Q2Q % growth | 48.345M 50.19% | 47.508M | 837K | 1.76% |
| Q4 2022 Q2Q % growth | 61.884M 230.14% | 46.018M | 15.866M | 34.48% |
| Q3 2022 Q2Q % growth | 99.135M 719.64% | 95.516M | 3.619M | 3.79% |
| Q2 2022 Q2Q % growth | 26.972M 250.10% | 29.124M | -2.152M | -7.39% |
| Q1 2022 Q2Q % growth | 32.189M | 23.226M | 8.963M | 38.59% |
| Q4 2021 Q2Q % growth | 18.745M | 21.139M | -2.394M | -11.33% |
| Q3 2021 Q2Q % growth | 12.095M | 10.38M | 1.715M | 16.52% |
| Q2 2021 Q2Q % growth | 7.704M | 4.048M | 3.656M | 90.32% |
| Q1 2021 Q2Q % growth | 7.931M | -7.931M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -133.33% | -133.33% | -2.17% | -2.17% |
| Revenue | 0.11% | 0.11% | 0% | 0.03% |